Pathophysiologic and clinical implications of molecular profiles resultant from deletion 5q
- PMID: 35617825
- PMCID: PMC9130225
- DOI: 10.1016/j.ebiom.2022.104059
Pathophysiologic and clinical implications of molecular profiles resultant from deletion 5q
Abstract
Background: Haploinsufficiency (HI) resulting from deletion of the long arm of chromosome 5 [del(5q)] and the accompanied loss of heterozygosity are likely key pathogenic factors in del(5q) myeloid neoplasia (MN) although the consequences of del(5q) have not been yet clarified.
Methods: Here, we explored mutations, gene expression and clinical phenotypes of 388 del(5q) vs. 841 diploid cases with MN [82% myelodysplastic syndromes (MDS)].
Findings: Del(5q) resulted as founder (better prognosis) or secondary hit (preceded by TP53 mutations). Using Bayesian prediction analyses on 57 HI marker genes we established the minimal del(5q) gene signature that distinguishes del(5q) from diploid cases. Clusters of diploid cases mimicking the del(5q) signature support the overall importance of del(5q) genes in the pathogenesis of MDS in general. Sub-clusters within del(5q) patients pointed towards the inherent intrapatient heterogeneity of HI genes.
Interpretation: The underlying clonal expansion drive results from a balance between the "HI-driver" genes (e.g., CSNK1A1, CTNNA1, TCERG1) and the proapoptotic "HI-anti-drivers" (e.g., RPS14, PURA, SIL1). The residual essential clonal expansion drive allows for selection of accelerator mutations such as TP53 (denominating poor) and CSNK1A1 mutations (with a better prognosis) which overcome pro-apoptotic genes (e.g., p21, BAD, BAX), resulting in a clonal expansion. In summary, we describe the complete picture of del(5q) MN identifying the crucial genes, gene clusters and clonal hierarchy dictating the clinical course of del(5q) patients.
Funding: Torsten Haferlach Leukemia Diagnostics Foundation. US National Institute of Health (NIH) grants R35 HL135795, R01HL123904, R01 HL118281, R01 HL128425, R01 HL132071, and a grant from Edward P. Evans Foundation.
Keywords: 5q deletion; CSNK1A1; Haploinsufficiency; Myelodysplastic syndromes; TP53.
Copyright © 2022 The Author(s). Published by Elsevier B.V. All rights reserved.
Conflict of interest statement
Dr. Sekeres received consultation fees from BMS/Celgene and Kurome. All the other authors declare no conflicts interests.
Figures
References
-
- Giagounidis A.A.N., Germing U., Haase S., et al. Clinical, morphological, cytogenetic, and prognostic features of patients with myelodysplastic syndromes and del(5q) including band q31. Leukemia. 2004;18(1):113–119. - PubMed
-
- Arber D.A., Orazi A., Hasserjian R., et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–2405. - PubMed
-
- Van den Berghe H., Cassiman J.J., David G., Fryns J.P., Michaux J.L., Sokal G. Distinct haematological disorder with deletion of long arm of no. 5 chromosome. Nature. 1974;251(5474):437–438. - PubMed
-
- Boultwood J., Fidler C., Soularue P., et al. Novel genes mapping to the critical region of the 5q- syndrome. Genomics. 1997;45(1):88–96. - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
